Monoclonal antibody therapies have elevated precision medicine by enabling targeted therapy and providing personalized treatment options. A better understanding of the underlying molecular pathologies in various diseases has helped identify specific therapeutic targets for the development of monoclonal antibody (mAb) drugs. Hence, several mAb drug development also requires the co-development of molecular biomarker-based diagnostics in order to select patients who are most likely to respond.
In the last few years, there has seen an increase in the approval of antibody drugs for clinical use, mainly for cancer and auto-immune diseases. Many more are under clinical evaluation anticipating approval in the coming years. Below we discuss the disease areas where antibody therapies have demonstrated significant success.

we are recruiting